Antihypertensive Agents Not Tied to Higher Risk for Depression
Depression rates down with nine antihypertensive agents, including enalapril, amlodipine, atenolol (Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - November 11, 2014 Category: Psychiatry Tags: Cardiology, Family Medicine, Geriatrics, Internal Medicine, Neurology, Pharmacy, Psychiatry, Journal, Source Type: news
Heart failure drug could 'cut deaths by a fifth'
Conclusion
This was a well conducted study that achieved impressive results.
In this 27 month-long randomised controlled trial of 8,442 people with heart failure and an ejection fraction of 40% or less, compared to enalpril, the new drug LCZ696:
reduced the risk of death from cardiovascular disease or the risk of hospitalisation for heart failure by 20%
reduced the risk of death from cardiovascular disease by 20%
reduced the risk of hospitalisation for heart failure by 21%
reduced the risk of death from any cause by 16%
Marketing authorisation is now required before it can be sold. The developer of th...
Source: NHS News Feed - September 1, 2014 Category: Consumer Health News Tags: Heart/lungs Source Type: news
3 Questions That Remain After Novartis' Blockbuster Trial Result
The release of PARADIGM-HF trial in the New England Journal of Medicine, with its stunning results for Novartis’ experimental combination drug, is good news for patients with heart failure and their doctors. The trial was ended early because the combination drug, which included sacubitril (an experimental drug) and valsartan (a current therapy), demonstrated superiority over enalapril (another current therapy). The combination drug reduced the risk of death from heart disease by 20%, death from any cause by 16%, and first hospitalization for heart failure by 21%. Moreover, there was no indication of any safety proble...
Source: Forbes.com Healthcare News - August 30, 2014 Category: Pharmaceuticals Authors: Harlan Krumholz Source Type: news
Novel Heart Failure Drug Combo Cuts CV Mortality More Than Enalapril (FREE)
By Joe Elia
Edited by Susan Sadoughi, MD, and Richard Saitz, MD, MPH, FACP, FASAM
LCZ696, an experimental compound that inhibits both angiotensin and neprilysin, "may well represent a new threshold" in treating heart failure, according to an editorialist in the New England Journal of Medicine. Neprilysin is an endopeptidase that degrades certain endogenous vasoactive peptides; its inhibition increases … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - August 30, 2014 Category: Primary Care Source Type: news
Epaned (Enalapril Powder for Oral Solution) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 29, 2013 Category: Drugs & Pharmacology Source Type: news
Great CPC: Metformin toxicity
3.5 out of 5 stars
Case 23-2013: a 54-Year-old Woman with Abdominal Pain, Vomiting, and Confusion. Kalantar-Zadeh K et al. N Engl J Med 2013 Jul 25;369:374-382.
Full Text
This is a very instructive case discussion from the Massachusetts General Hospital. A plane was diverted to Boston because one passenger, a 54-year-old woman, developed increasing abdominal pain and vomiting, along with decreasing mental status. After the plane landed, EMS found that here vital signs were fairly unremarkable (HR = 52 bpm). She was not hypoglycemic.
Her medical history included type-2 diabetes, hypertension, and chronic renal disease. Med...
Source: The Poison Review - July 26, 2013 Category: Toxicology Authors: Leon Tags: Medical acute pancreatitis anion gap metabolic acidosis case discussion case records of the massachusetts general hospital metformin toxicity Source Type: news
Case report: hearing loss after snorting oxymorphone
2.5 out of 5 stars
Oxymorphone Insufflation Associated with Acute Sensorineural Hearing Loss: Case Files of the University of Massachusetts Medical Toxicology Fellowship. Boyle KL, Rosenbaum CD. J Med Toxicol 2013 Jun:9:179-183.
No abstract available
This case report describes a 37-year-old man who experienced transient partial hearing loss after snorting crushed Opana® (oxymorphone). The case itself isn’t much, but it provides the opportunity for the authors to present a good discussion of drug-induced ototoxicity.
Although opiate-associated hearing loss (OAHL) is well described, the authors state that this is th...
Source: The Poison Review - June 18, 2013 Category: Toxicology Authors: Leon Tags: Medical narcotics opana opiates ototoxicity sensorineural hearing loss Source Type: news
Preventing Heart Damage From Chemotherapy: OVERCOME TrialPreventing Heart Damage From Chemotherapy: OVERCOME Trial
A pilot study shows that the combination of enalapril plus carvedilol prevented left ventricular damage in cancer patients undergoing intensive chemotherapy. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 11, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
enalapril and hydrochlorothiazide, Vaseretic
Title: enalapril and hydrochlorothiazide, VasereticCategory: MedicationsCreated: 4/3/1999 4:02:00 PMLast Editorial Review: 3/8/2013 12:00:00 AM (Source: MedicineNet High Blood Pressure General)
Source: MedicineNet High Blood Pressure General - March 8, 2013 Category: Cardiology Source Type: news
Review: Postpartum management of hypertension
Source: BMJ
Area: News
The British Medical Journal has featured a review on the postpartum management of hypertension. The most common cause of postpartum hypertension is gestational hypertension or pre-eclampsia that persists after delivery.
In terms of medical management, the review states that suggested first line antihypertensive drugs that are safe in breastfeeding mothers include labetalol, nifedipine, and enalapril. (Source: NeLM - Cardiovascular Medicine)
Source: NeLM - Cardiovascular Medicine - February 26, 2013 Category: Cardiology Source Type: news
